View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Insulet Corporation: Update to credit analysis following ratings upgra...

Our credit view of this issuer reflects its geographic diversification, strong competitive position and credit metrics, but single product line focus

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 28, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 26, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Moody's Ratings upgrades Insulet's CFR to Ba2; outlook is stable

Moody's Ratings (Moody's) upgraded Insulet Corporation's ("Insulet") corporate family rating ("CFR") to Ba2 from Ba3 and Probability of Default Rating ("PDR") to Ba2-PD from Ba3-PD. Concurrently, we upgraded the ratings on Insulet's senior secured term loan and senior secured revolving credit facili...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 23, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Research Team ACF
  • Research Team ACF

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...

Moody's Ratings upgrades Insulet's CFR to Ba3; outlook remains positiv...

Moody's Ratings (Moody's) upgraded Insulet Corporation's ("Insulet") Corporate Family Rating (CFR) to Ba3 from B1 and Probability of Default Rating ("PDR") to Ba3-PD from B1-PD. Concurrently, we affirmed the Ba2 rating on Insulet's senior secured term loan and assigned a Ba2 rating to Insulet's new ...

Research Team ACF
  • Research Team ACF

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...

Insulet Corporation: Update to credit analysis following CFR upgrade

Our credit view of this issuer reflects its strong competitive position, but single product line focus.

Moody's Ratings upgrades Insulet's CFR to B1; outlook remains positive

Moody's Ratings (Moody's) upgraded Insulet Corporation's ("Insulet") Corporate Family Rating (CFR) to B1 from B2 and Probability of Default Rating ("PDR") to B1-PD from B2-PD. Concurrently, we affirmed the Ba2 ratings on Insulet's senior secured credit facilities, including the senior secured term l...

Insulet Corporation: Credit view update following outlook revision to ...

Our credit view of this issuer reflects its very strong liquidity, offset by its executional risks related to new product development and commercialization.

Moody's affirms Insulet B2 CFR; outlook revised to positive from stabl...

Moody's Investors Service ("Moody's") affirmed the ratings of Insulet Corporation, ("Insulet") including the Corporate Family Rating ("CFR") at B2, and Probability of Default Rating ("PDR") at B2-PD. At the same time, Moody's upgraded Insulet's ratings on the senior secured term loan and senior secu...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Insulet Corporation: Continued revenue growth supports leverage reduct...

Our credit view of this issuer reflects its very strong liquidity, constrained by its competition in insulin management market.

Insulet Corporation: Strong earnings growth will enable further deleve...

Our credit view of this issuer reflects its very strong liquidity, constrained by narrow focus on insulin management market and very high but rapidly improving leverage.

INSULET sees an upgrade to Slightly Positive due to a better fundament...

The general evaluation of INSULET (US), a company active in the Medical Equipment industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date February 15, 2022, the closing price was USD...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Tables: January 1, 2022

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch